RPG Life Sciences (NSE:RPGLIFE) EBIT: ₹1,551 Mil (TTM As of Mar. 2026)


NSE:RPGLIFE RPG Life Sciences Ltd NSE:RPGLIFE
92 GF Score
Price ₹2,276.40
GF Value ₹2,359.83
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is RPG Life Sciences EBIT?

RPG Life Sciences NSE:RPGLIFE -0.54% 92 EBIT is ₹1,551 Mil as of Mar. 2026. GuruFocus rates NSE:RPGLIFE with a GF Score™ of 92/100 and a GF Value™ of ₹2,359.83 (Fairly Valued). The stock has 3 warning signs investors should review.

RPG Life Sciences's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ₹406 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,551 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. RPG Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 was 19.66%. RPG Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 48.82%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. RPG Life Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.43%.


RPG Life Sciences  (NSE:RPGLIFE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

RPG Life Sciences's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=1083.6 * ( 1 - 25.62% )/( (0 + 4099.1)/ 1 )
=805.98168/4099.1
=19.66 %

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

RPG Life Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=1623.6/( ( (0 + max(0, 0)) + (2117.2 + max(1208.2, 0)) )/ 1 )
=1623.6/( ( 0 + 3325.4 )/ 1 )
=1623.6/3325.4
=48.82 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1166.8 + 1238.4 + 342) - (984.9 + 0 + 554.1)
=1208.2

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

RPG Life Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=1550.9/35001.814
=4.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RPG Life Sciences EBIT Related Terms


RPG Life Sciences EBIT Historical Data

* Premium members only.

The historical data trend for RPG Life Sciences's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RPG Life Sciences EBIT Chart

RPG Life Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 736.90 919.90 1,182.90 2,335.00 1,550.90

RPG Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,350.80 355.60 495.70 293.70 405.90

NSE:RPGLIFE vs ZTS: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, RPG Life Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RPG Life Sciences EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, RPG Life Sciences's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where RPG Life Sciences's EV-to-EBIT falls into.


NSE:RPGLIFE
92GF Score
RPG Life Sciences Ltd NSE:RPGLIFE
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RPG Life Sciences EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,551 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹1,551 Mil mean?
RPG Life Sciences (NSE:RPGLIFE) has a EBIT of ₹1,551 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on RPG Life Sciences.
Is RPG Life Sciences' EBIT too high?
RPG Life Sciences' current EBIT is ₹1,551 Mil. Overall, RPG Life Sciences has a GF Score™ of 92/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RPG Life Sciences' EBIT compare to ZTS?
RPG Life Sciences' EBIT of ₹1,551 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on RPG Life Sciences. RPG Life Sciences's current EBIT is ₹1,551 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RPG Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RPG Life Sciences (NSE:RPGLIFE) is currently considered Fairly Valued. The stock's GF Value™ is ₹2,359.83, compared to a current price of ₹2,276.40 — trading 3.5% below its estimated fair value. The current EBIT is ₹1,551 Mil. RPG Life Sciences' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For RPG Life Sciences (NSE:RPGLIFE), the current EBIT is ₹1,551 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RPG Life Sciences (NSE:RPGLIFE) Overvalued in 2026?

Based on GuruFocus' analysis, RPG Life Sciences stock appears to be undervalued. The current stock price of ₹2,276.40 is trading 3.5% below its estimated GF Value™ of ₹2,359.83. GuruFocus considers RPG Life Sciences to be Fairly Valued.

Key valuation signals for NSE:RPGLIFE:

  • EBIT: ₹1,551 Mil
  • GF Value™: ₹2,359.83 vs. price of ₹2,276.40 (3.5% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the NSE:RPGLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


RPG Life Sciences Business Description

Other Exchanges 532983:India
Address 463, Dr. Annie Besant Road, RPG House, Near Old Passport Office, Worli, Mumbai, MH, IND, 400030
RPG Life Sciences Ltd is an integrated pharmaceutical company. Its only reportable segment is the manufacturing and marketing of pharmaceutical products. Geographically, it derives a majority of revenue from India. The company operates across Domestic Formulations, International Formulations and Active Pharmaceutical Ingredients (API). It focuses on Nephrology, Oncology, Urology, Respiratory, Gastrointestinal, Cardiovascular, Gynaecology and Pediatrics, Vitamins and Minerals, Pain Management, Neurology, Anti-Dengue, Anti-Diabetic, and Derma.
92GF Score

Get the complete analysis for NSE:RPGLIFE

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,276.40
Price
₹2,359.83
GF Value